Home › Funds › Hardman Johnston Global Advisors LLC › BSX
Hardman Johnston Global Advisors LLC position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Hardman Johnston Global Advisors LLC reported holding 235,344 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$10.3M, representing 0.31% of its reported portfolio and ranking #42 among its reported holdings. Hardman Johnston Global Advisors LLC has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Hardman Johnston Global Advisors LLC's BSX position evolved
Hardman Johnston Global Advisors LLC first disclosed a stake in BSX in Q3 2023 at 650,130 shares (US$34.3M). The position peaked in Q1 2024 at 652,614 shares, worth US$44.7M. Across 13 filings, Hardman Johnston Global Advisors LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 235,344 shares valued at US$10.3M — an increase of 66,984 shares quarter over quarter.. Notable position changes include a 46% trim in Q2 2024 (shares rose 9% over the following quarter), a 28% trim in Q3 2024 (shares rose 7% over the following quarter), a 40% increase in Q3 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 650.13K | $34.33M | New |
| Q4 2023 | 674.94K | $39.02M | Add |
| Q1 2024 | 652.61K | $44.70M | Reduce |
| Q2 2024 | 354.54K | $27.30M | Reduce |
| Q3 2024 | 256.99K | $21.54M | Reduce |
| Q4 2024 | 326.90K | $29.20M | Add |
| Q1 2025 | 287.25K | $28.98M | Reduce |
| Q2 2025 | 233.50K | $25.08M | Reduce |
| Q3 2025 | 237.35K | $23.17M | Add |
| Q4 2025 | 228.26K | $21.76M | Reduce |
| Q1 2026 | 166.02K | $10.42M | Reduce |
| Q2 2026 | 168.36K | $7.19M | Add |
| Q3 2026 | 235.34K | $10.27M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), Arrowstreet Capital (US$1.24B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 58.62M sh · $2.56B · Q3 2026
- MFS Investment Management 43.05M sh · $2.29B · Q3 2026
- Arrowstreet Capital 28.47M sh · $1.24B · Q3 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Two Sigma Investments 20.01M sh · $873.30M · Q3 2026
More on Hardman Johnston Global Advisors LLC
FAQ
How long has Hardman Johnston Global Advisors LLC held BSX?
Hardman Johnston Global Advisors LLC has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Hardman Johnston Global Advisors LLC's current position in BSX?
As of Q3 2026, Hardman Johnston Global Advisors LLC holds 235.34K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $10.27M, representing 0.31% of its reported portfolio and ranking #42.
Has Hardman Johnston Global Advisors LLC been buying or selling BSX?
In the latest 13F filing (Q3 2026), Hardman Johnston Global Advisors LLC increased its position in BSX. The position peaked in Q1 2024 at 652.61K shares.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, Arrowstreet Capital, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.